Published in J Am Heart Assoc on January 08, 2015
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med (1991) 6.13
Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA (2008) 4.41
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA (2007) 3.50
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev (2006) 3.26
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol (2008) 2.51
A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest (1980) 2.27
Prognostic value of troponin after elective percutaneous coronary intervention: A meta-analysis. Catheter Cardiovasc Interv (2008) 1.99
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol (2013) 1.86
Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J (2004) 1.68
High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol (2010) 1.62
Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation (2009) 1.56
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol (2009) 1.52
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J (2013) 1.46
Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv (2008) 1.45
Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J (2013) 1.40
Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res (2009) 1.31
Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med (2012) 1.26
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation (2013) 1.20
Inflammation modulates human HDL composition and function in vivo. Atherosclerosis (2012) 1.18
Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation (2002) 1.18
High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res (2013) 1.09
Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol (1999) 1.08
Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol (2007) 0.98
Smoking prevents the intravascular remodeling of high-density lipoprotein particles: implications for reverse cholesterol transport. Metabolism (2004) 0.91
Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb (2010) 0.89
An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women's Genome Health Study. Circ Cardiovasc Genet (2009) 0.89
Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (1995) 0.83
Slow but steady progress towards understanding peri-procedural myocardial infarction. Eur Heart J (2013) 0.81
Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention. Am J Cardiol (2012) 0.78